QurieGen (est. April 2022) aspires to revolutionize drug discovery. This biotech startup leverages a proprietary method of mapping cellular responses to drug stimuli. Uniquely, this disruptive technology reveals the full picture of the signaling pathways, replacing many different, mutually incompatible analytical tools that at best provide an incomplete picture of the cell response to drug perturbations. The QurieGen R&D team will build a unique AI platform to predict cellular responses to drug candidate molecules, enabling data-driven discovery. Currently, we are raising seed investment to accelerate our operations. Please contact us if you are interested in investing in QurieGen.
Company Details
- Employees
- 6
- Founded
- 2022
- Address
- Heyendaalseweg 135, Nijmegen,gelderland 6525 Aj,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.quriegen.com
- HQ
- Nijmegen, Gelderland
Quriegen Questions
Quriegen's website is http://www.quriegen.com
Quriegen's LinkedIn profile is https://nl.linkedin.com/company/quriegen
Quriegen has
6 employees.
View email and phone details for 6
employees at Quriegen.
Quriegen's industry is
Biotechnology Research
Quriegen's top competitors are
Spotonme,
Cubiq Technologies,
Besirius,
Aevai Health,
Belmont Diagnostics,
Manitty,
Horaizon Labs,
Gamma Pulse,
Moremovement,
Nato Diana.
Quriegen's categories are Biotechnology Research
Quriegen's founding year is 2022
